Cerevel Therapeutics Holdings, Inc. Quarterly Income Tax Expense (Benefit) in USD from Q1 2020 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Cerevel Therapeutics Holdings, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q1 2020 to Q1 2024.
  • Cerevel Therapeutics Holdings, Inc. Income Tax Expense (Benefit) for the quarter ending March 31, 2024 was $138K, a 62.4% increase year-over-year.
  • Cerevel Therapeutics Holdings, Inc. Income Tax Expense (Benefit) for the twelve months ending March 31, 2024 was $556K.
  • Cerevel Therapeutics Holdings, Inc. annual Income Tax Expense (Benefit) for 2023 was $503K, a 214% increase from 2022.
  • Cerevel Therapeutics Holdings, Inc. annual Income Tax Expense (Benefit) for 2022 was $160K.
  • Cerevel Therapeutics Holdings, Inc. annual Income Tax Expense (Benefit) for 2020 was -$24K, a 153% decline from 2019.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $556K $138K +$53K +62.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $503K $188K Oct 1, 2023 Dec 31, 2023 10-K 2024-02-27
Q3 2023 $123K Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-01
Q2 2023 $107K Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-02
Q1 2023 $85K Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q1 2021 -$24K $0 $0 Jan 1, 2021 Mar 31, 2021 10-Q 2021-05-17
Q4 2020 -$24K -$3K Oct 1, 2020 Dec 31, 2020 10-K 2023-02-22
Q3 2020 -$5K Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$16K Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-11
Q1 2020 $0 Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-17
* An asterisk sign (*) next to the value indicates that the value is likely invalid.